Share capital increase
On 29 October 2010 the general assembly in DiaGenic ASA resolved a private placement of 140 million new shares and a subsequent offering of up to 60 million new shares, both at a subscription price of NOK 0.50 per share. The share capital increase from the private placement of 140 million new shares has now been registered with the Norwegian Register of Business Enterprises. Following the registration, DiaGenic’s share capital is NOK 10,511,826, divided into 210,236,520 shares, each with a nominal value of NOK 0.05. The Articles of Association of the Company have been revised accordingly. Please find attached updated company certificate.
The new shares in DiaGenic ASA are from now on tradable on Oslo Børs.
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act).
Contact:
Erik Christensen, CEO
Telephone: 47 95939918
e-mail: erik.christensen@diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com